Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Ra Pharmaceuticals, Inc. (RARX) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/02/2020 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "ARTICLE I",
"ARTICLE I OFFICES",
"EXHITBIT 99.1"
03/31/2020 8-K Quarterly results
03/13/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Second Amendment to Lease Agreement, by and between Ra Pharmaceuticals, Inc. and HCP/King 87 CPD LLC"
02/28/2020 8-K Quarterly results
12/18/2019 8-K Submission of Matters to a Vote of Security Holders, Other Events
11/25/2019 8-K Other Events
10/10/2019 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among UCB S.A., Franq Merger Sub, Inc. and Ra Pharmaceuticals, Inc",
"UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases"
07/26/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between the Company and Jefferies LLC, BMO Capital Markets Corp. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP"
07/16/2019 8-K Entry into a Material Definitive Agreement
06/12/2019 8-K Submission of Matters to a Vote of Security Holders
05/09/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Opinion of Latham & Watkins LLP",
"Open Market Sale AgreementSM, by and between Ra Pharmaceuticals, Inc. and Jefferies LLC"
12/14/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between the Company and Jefferies LLC, BMO Capital Markets Corp. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP"
12/11/2018 8-K Termination of a Material Definitive Agreement
12/10/2018 8-K Other Events
11/15/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/25/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/29/2018 8-K Submission of Matters to a Vote of Security Holders
06/07/2018 8-K Investor presentation
Docs: "Corporate slide presentation of Ra Pharmaceuticals, Inc., dated June 2018"
05/09/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Opinion of Latham & Watkins LLP",
"Sales Agreement, by and between Ra Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated"
02/15/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between the Company and Credit Suisse Securities (USA) LLC, Jefferies LLC and BMO Capital Markets Corp., as representatives of the several underwriters party thereto",
"Opinion of Goodwin Procter LLP",
"Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock"
02/13/2018 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock"
12/08/2017 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria",
"Investor Presentation"
06/26/2017 8-K Quarterly results
04/04/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ra Pharmaceuticals, Inc., corporate presentation"
12/02/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy